AstraZeneca is investing $445 million to expand its manufacturing facility in Coppell, Texas. The expansion project will double the production of Lokelma (sodium zirconium cyclosilicate), a drug for treating hyperkalemia (high levels of potassium in the blood).

The investment of $445 million to expand the facility follows the groundbreaking earlier this month (October 2025) of a new manufacturing facility in Albemarle County, Virginia, which will support AstraZeneca’s weight management and metabolic drug portfolio and its antibody drug conjugate cancer pipeline. Both are part of AstraZeneca’s $50-billion investment in US R&D and manufacturing over the next five years that was announced in July 2025. 

AstraZeneca’s Coppell facility is the sole global manufacturing facility of Lokelma to more than 50 countries around the world, including the US.

Through the expansion and development of a new 9,000-square-foot-building, two manufacturing lines will be added along with enhancements to support drug-substance and drug-product laboratory testing, warehousing, additional manufacturing utilities, and administrative space. 

Source: AstraZeneca